{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:37:31Z","timestamp":1787341051893,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01 AA025365"],"award-info":[{"award-number":["R01 AA025365"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04112-4","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:04:17Z","timestamp":1780502657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glutamate- and GABA-targeted drugs for Co-occurring bipolar and alcohol use disorders: a randomized, double-blind, placebo-controlled, crossover study of N-acetylcysteine, gabapentin, and placebo"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-7871","authenticated-orcid":false,"given":"James J.","family":"Prisciandaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Mellick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiya","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan K.","family":"Tolliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-6576","authenticated-orcid":false,"given":"Raymond F.","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"4112_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jad.2016.07.011","volume":"206","author":"GE Hunt","year":"2016","unstructured":"Hunt GE, Malhi GS, Cleary M, Lai HM, Sitharthan T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990\u20132015: systematic review and meta-analysis. J Affect Disord. 2016;206:331\u201349.","journal-title":"J Affect Disord"},{"key":"4112_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11920-012-0320-9","volume":"14","author":"CK Farren","year":"2012","unstructured":"Farren CK, Hill KP, Weiss RD. Bipolar disorder and alcohol use disorder: a review. Curr Psychiatry Rep. 2012;14:659\u201366.","journal-title":"Curr Psychiatry Rep"},{"key":"4112_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2012.06.012","volume":"145","author":"JJ Rakofsky","year":"2013","unstructured":"Rakofsky JJ, Dunlop BW. Do alcohol use disorders destabilize the course of bipolar disorder? J Affect Disord. 2013;145:1\u201310.","journal-title":"J Affect Disord"},{"key":"4112_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40263-017-0449-5","volume":"31","author":"A Naglich","year":"2017","unstructured":"Naglich A, Adinoff B, Brown ES. Pharmacological treatment of bipolar disorder with comorbid alcohol use disorder. CNS Drugs. 2017;31:665\u201374.","journal-title":"CNS Drugs"},{"key":"4112_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","volume":"62","author":"IM Salloum","year":"2005","unstructured":"Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37\u201345.","journal-title":"Arch Gen Psychiatry"},{"key":"4112_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/wps.20227","volume":"14","author":"TR Insel","year":"2015","unstructured":"Insel TR. The NIMH experimental medicine initiative. World Psychiatry. 2015;14:151\u20133.","journal-title":"World Psychiatry"},{"key":"4112_CR7","unstructured":"Hassel B, Dingledine R Glutamate. In: Siegel GJ, Albers RW, Brady ST, Price DL, editors. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. London, UK: Elsevier Academic Press; 2006. pp. 267-90."},{"key":"4112_CR8","unstructured":"Olsen RW, Betz H GABA and glycine. In: Siegel GJ, Albers RW, Brady ST, Price DL, editors. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. London, UK: Elsevier Academic Press; 2006. pp. 291-301"},{"key":"4112_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0028-y","volume":"50","author":"Y Lee","year":"2018","unstructured":"Lee Y, Zhang Y, Kim S, Han K. Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"4112_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.neubiorev.2019.05.027","volume":"103","author":"FAJ Gigase","year":"2019","unstructured":"Gigase FAJ, Snijders G, Boks MP, de Witte LD. Neurons and glial cells in bipolar disorder: a systematic review of postmortem brain studies of cell number and size. Neurosci Biobehav Rev. 2019;103:150\u201362.","journal-title":"Neurosci Biobehav Rev"},{"issue":"Suppl 1","key":"4112_CR11","first-page":"44","volume":"5","author":"CJ Blacker","year":"2020","unstructured":"Blacker CJ, Millischer V, Webb LM, Ho AMC, Schalling M, Frye MA, et al. EAAT2 as a research target in bipolar disorder and unipolar depression: a systematic review. Mol Neuropsychiatry. 2020;5(Suppl 1):44\u201359.","journal-title":"Mol Neuropsychiatry"},{"key":"4112_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.psychres.2017.07.059","volume":"257","author":"CJ Blacker","year":"2017","unstructured":"Blacker CJ, Lewis CP, Frye MA, Veldic M. Metabotropic glutamate receptors as emerging research targets in bipolar disorder. Psychiatry Research. 2017;257:327\u201337.","journal-title":"Psychiatry Research"},{"key":"4112_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/npp.2016.149","volume":"42","author":"RT de Sousa","year":"2017","unstructured":"de Sousa RT, Loch AA, Carvalho AF, Brunoni AR, Haddad MR, Henter ID, et al. Genetic studies on the tripartite glutamate synapse in the pathophysiology and therapeutics of mood disorders. Neuropsychopharmacology. 2017;42:787\u2013800.","journal-title":"Neuropsychopharmacology"},{"key":"4112_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ajmg.b.30887","volume":"150b","author":"H Le-Niculescu","year":"2009","unstructured":"Le-Niculescu H, Patel SD, Bhat M, Kuczenski R, Faraone SV, Tsuang MT, et al. Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms. Am J Med Genet B, Neuropsychiatr Genet. 2009;150b:155\u201381.","journal-title":"Am J Med Genet B, Neuropsychiatr Genet"},{"key":"4112_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21973","volume":"71","author":"SH Fatemi","year":"2017","unstructured":"Fatemi SH, Folsom TD, Thuras PD. GABAA and GABAB receptor dysregulation in superior frontal cortex of subjects with schizophrenia and bipolar disorder. Synapse. 2017;71:e21973.","journal-title":"Synapse"},{"key":"4112_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.schres.2004.02.017","volume":"72","author":"SH Fatemi","year":"2005","unstructured":"Fatemi SH, Stary JM, Earle JA, Araghi-Niknam M, Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res. 2005;72:109\u201322.","journal-title":"Schizophr Res"},{"key":"4112_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0006-3223(03)00689-9","volume":"55","author":"Y Horiuchi","year":"2004","unstructured":"Horiuchi Y, Nakayama J, Ishiguro H, Ohtsuki T, Detera-Wadleigh SD, Toyota T, et al. Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders. Biol Psychiatry. 2004;55:40\u20135.","journal-title":"Biol Psychiatry"},{"key":"4112_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/sj.mp.4000953","volume":"7","author":"I Massat","year":"2002","unstructured":"Massat I, Souery D, Del-Favero J, Oruc L, Noethen MM, Blackwood D, et al. Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Mol Psychiatry. 2002;7:201\u20137.","journal-title":"Mol Psychiatry"},{"key":"4112_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.neulet.2005.02.010","volume":"381","author":"K Otani","year":"2005","unstructured":"Otani K, Ujike H, Tanaka Y, Morita Y, Katsu T, Nomura A, et al. The GABA type a receptor alpha5 subunit gene is associated with bipolar I disorder. Neuroscience Lett. 2005;381:108\u201313.","journal-title":"Neuroscience Lett"},{"key":"4112_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1399-5618.2012.01033.x","volume":"14","author":"AD Gigante","year":"2012","unstructured":"Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012;14:478\u201387.","journal-title":"Bipolar Disord"},{"key":"4112_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2021.01.096","volume":"47","author":"E Scotti-Muzzi","year":"2021","unstructured":"Scotti-Muzzi E, Umla-Runge K, Soeiro-de-Souza MG. Anterior cingulate cortex neurometabolites in bipolar disorder are influenced by mood state and medication: a meta-analysis of (1)H-MRS studies. Eur Neuropsychopharmacol. 2021;47:62\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4112_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.biopsych.2022.08.004","volume":"93","author":"M Simmonite","year":"2023","unstructured":"Simmonite M, Steeby CJ, Taylor SF. Medial frontal cortex GABA concentrations in psychosis spectrum and mood disorders: a meta-analysis of proton magnetic resonance spectroscopy studies. Biol Psychiatry. 2023;93:125\u201336.","journal-title":"Biol Psychiatry"},{"key":"4112_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bcp.2007.06.039","volume":"75","author":"JT Gass","year":"2008","unstructured":"Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008;75:218\u201365.","journal-title":"Biochem Pharmacol"},{"key":"4112_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archpsyc.63.9.957","volume":"63","author":"JH Krystal","year":"2006","unstructured":"Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry. 2006;63:957\u201368.","journal-title":"Arch Gen Psychiatry"},{"key":"4112_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrn2515","volume":"10","author":"PW Kalivas","year":"2009","unstructured":"Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10:561\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"4112_CR26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760\u201373.","journal-title":"Lancet Psychiatry"},{"key":"4112_CR27","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1111\/acer.12149","volume":"37","author":"G Ende","year":"2013","unstructured":"Ende G, Hermann D, Demirakca T, Hoerst M, Tunc-Skarka N, Weber-Fahr W, et al. Loss of control of alcohol use and severity of alcohol dependence in non-treatment-seeking heavy drinkers are related to lower glutamate in frontal white matter. Alcohol, Clin Exp Res. 2013;37:1643\u20139.","journal-title":"Alcohol, Clin Exp Res"},{"key":"4112_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugalcdep.2012.03.012","volume":"125","author":"A Mon","year":"2012","unstructured":"Mon A, Durazzo TC, Meyerhoff DJ. Glutamate, GABA, and other cortical metabolite concentrations during early abstinence from alcohol and their associations with neurocognitive changes. Drug Alcohol Depend. 2012;125:27\u201336.","journal-title":"Drug Alcohol Depend"},{"key":"4112_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/acer.13931","volume":"43","author":"JJ Prisciandaro","year":"2019","unstructured":"Prisciandaro JJ, Schacht JP, Prescot AP, Renshaw PF, Brown TR, Anton RF. Brain glutamate, GABA, and glutamine levels and associations with recent drinking in treatment-na\u00efve individuals with alcohol use disorder versus light drinkers. Alcohol Clin Exp Res. 2019;43:221\u20136.","journal-title":"Alcohol Clin Exp Res"},{"key":"4112_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/npp.2011.20","volume":"36","author":"R Thoma","year":"2011","unstructured":"Thoma R, Mullins P, Ruhl D, Monnig M, Yeo RA, Caprihan A, et al. Perturbation of the glutamate-glutamine system in alcohol dependence and remission. Neuropsychopharmacology. 2011;36:1359\u201365.","journal-title":"Neuropsychopharmacology"},{"key":"4112_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.biopsych.2011.07.034","volume":"71","author":"D Hermann","year":"2012","unstructured":"Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N, et al. Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry. 2012;71:1015\u201321.","journal-title":"Biol Psychiatry"},{"key":"4112_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jpsychires.2009.09.006","volume":"44","author":"FG Nery","year":"2010","unstructured":"Nery FG, Stanley JA, Chen H-H, Hatch JP, Nicoletti MA, Monkul ES, et al. Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. J Psychiatric Res. 2010;44:278\u201385.","journal-title":"J Psychiatric Res"},{"key":"4112_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.141","volume":"7","author":"JJ Prisciandaro","year":"2017","unstructured":"Prisciandaro JJ, Tolliver BK, Prescot AP, Brenner HM, Renshaw PF, Brown TR, et al. Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017;7:e1163-e.","journal-title":"Transl Psychiatry"},{"key":"4112_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","volume":"6","author":"GJ Sills","year":"2006","unstructured":"Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6:108\u201313.","journal-title":"Curr Opin Pharmacol"},{"key":"4112_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/jpet.120.266056","volume":"374","author":"CP Taylor","year":"2020","unstructured":"Taylor CP, Harris EW. Analgesia with gabapentin and pregabalin may involve NMDA receptors, neurexins and thrombospondins. J Pharmacol Exp Ther. 2020;374:161\u201374.","journal-title":"J Pharmacol Exp Ther"},{"key":"4112_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ebiom.2019.03.008","volume":"42","author":"J Yu","year":"2019","unstructured":"Yu J, Wang DS, Bonin RP, Penna A, Alavian-Ghavanini A, Zurek AA, et al. Gabapentin increases expression of \u03b4 subunit-containing GABA(A) receptors. EBioMedicine. 2019;42:203\u201313.","journal-title":"EBioMedicine"},{"key":"4112_CR37","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/npp.2012.142","volume":"37","author":"K Cai","year":"2012","unstructured":"Cai K, Nanga RP, Lamprou L, Schinstine C, Elliott M, Hariharan H, et al. The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T (1)H-MRS study. Neuropsychopharmacology. 2012;37:2764\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"4112_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1212\/WNL.58.3.368","volume":"58","author":"R Kuzniecky","year":"2002","unstructured":"Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology. 2002;58:368\u201372.","journal-title":"Neurology"},{"key":"4112_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1528-1157.2000.tb00227.x","volume":"41","author":"OA Petroff","year":"2000","unstructured":"Petroff OA, Hyder F, Rothman DL, Mattson RH. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia. 2000;41:675\u201380.","journal-title":"Epilepsia"},{"key":"4112_CR40","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","volume":"180","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K, Book S, Hoffman M, Prisciandaro J, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180:728\u201336.","journal-title":"JAMA Intern Med"},{"key":"4112_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","volume":"174","author":"BJ Mason","year":"2014","unstructured":"Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:70\u20137.","journal-title":"JAMA Intern Med"},{"key":"4112_CR42","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/j.1530-0277.2009.00986.x","volume":"33","author":"H Myrick","year":"2009","unstructured":"Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582\u20138.","journal-title":"Alcohol Clin Exp Res"},{"key":"4112_CR43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1176\/appi.ajp.2021.20121757","volume":"178","author":"JJ Prisciandaro","year":"2021","unstructured":"Prisciandaro JJ, Hoffman M, Brown TR, Voronin K, Book S, Bristol E, et al. Effects of gabapentin on dorsal anterior cingulate cortex GABA and glutamate levels and their associations with abstinence in alcohol use disorder: a randomized clinical trial. Am J Psychiatry. 2021;178:829\u201337.","journal-title":"Am J Psychiatry"},{"key":"4112_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/BC.2009.033","volume":"390","author":"N Ballatori","year":"2009","unstructured":"Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem. 2009;390:191\u2013214.","journal-title":"Biol Chem"},{"key":"4112_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1471-4159.2006.03913.x","volume":"98","author":"LK Bak","year":"2006","unstructured":"Bak LK, Schousboe A, Waagepetersen HS. The glutamate\/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochemistry. 2006;98:641\u201353.","journal-title":"J Neurochemistry"},{"key":"4112_CR46","doi-asserted-by":"crossref","unstructured":"Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al. The multifaceted therapeutic role of N-Acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2020.","DOI":"10.2174\/1570159X19666201230144109"},{"key":"4112_CR47","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1007\/s00213-018-4997-2","volume":"235","author":"G McQueen","year":"2018","unstructured":"McQueen G, Lally J, Collier T, Zelaya F, Lythgoe DJ, Barker GJ, et al. Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. Psychopharmacology. 2018;235:3045\u201354.","journal-title":"Psychopharmacology"},{"key":"4112_CR48","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/npp.2012.66","volume":"37","author":"L Schmaal","year":"2012","unstructured":"Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012;37:2143\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"4112_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12900","volume":"26","author":"EA Woodcock","year":"2021","unstructured":"Woodcock EA, Lundahl LH, Khatib D, Stanley JA, Greenwald MK. N-acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate\/glutamine levels among cocaine-dependent individuals. Addict Bio. 2021;26:e12900.","journal-title":"Addict Bio"},{"key":"4112_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40263-014-0142-x","volume":"28","author":"EA McClure","year":"2014","unstructured":"McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014;28:95\u2013106.","journal-title":"CNS Drugs"},{"key":"4112_CR51","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/ajad.12620","volume":"26","author":"MS Duailibi","year":"2017","unstructured":"Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, LaRowe S, Berk M, et al. N-acetylcysteine in the treatment of craving in substance use disorders: systematic review and meta-analysis. Am J Addict. 2017;26:660\u20136.","journal-title":"Am J Addict"},{"key":"4112_CR52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/alcalc\/agad044","volume":"58","author":"KC Morley","year":"2023","unstructured":"Morley KC, Peruch S, Adams C, Towers E, Tremonti C, Watt J, et al. N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2023;58:553\u201360.","journal-title":"Alcohol Alcohol"},{"key":"4112_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bdi.13039","volume":"23","author":"FG Nery","year":"2020","unstructured":"Nery FG, Li W, DelBello MP, Welge JA. N-acetylcysteine as an adjunctive treatment for bipolar depression: a systematic review and meta-analysis of randomized controlled trials. Bipolar Disord. 2020;23:707\u201314.","journal-title":"Bipolar Disord"},{"key":"4112_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jad.2008.10.022","volume":"116","author":"AC Swann","year":"2009","unstructured":"Swann AC, Lijffijt M, Lane SD, Steinberg JL, Moeller FG. Severity of bipolar disorder is associated with impairment of response inhibition. J Affect Disord. 2009;116:30\u20136.","journal-title":"J Affect Disord"},{"key":"4112_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353\u20137.","journal-title":"Br J Addict"},{"key":"4112_CR56","volume-title":"Structured Clinical Interview for DSM-5","author":"MB First","year":"2015","unstructured":"First MB, Williams JBW, Karg RS, Spitzer RL. Structured Clinical Interview for DSM-5. Arlington, VA: American Psychiatric Association; 2015."},{"key":"4112_CR57","volume-title":"Alcohol Timeline Followback Users\u2019 Manual","author":"LC Sobell","year":"1995","unstructured":"Sobell LC, Sobell MB. Alcohol Timeline Followback Users\u2019 Manual. Toronto, Canada: Addiction Research Foundation; 1995."},{"key":"4112_CR58","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"4112_CR59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u201335.","journal-title":"Br J Psychiatry"},{"key":"4112_CR60","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266\u201377.","journal-title":"Am J Psychiatry"},{"key":"4112_CR61","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1080\/1354750X.2016.1269201","volume":"22","author":"VMS Ramanujam","year":"2017","unstructured":"Ramanujam VMS, Nayeem F, Anderson KE, Kuo Y-F, Chen N-W, Ju H, et al. Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial. Biomarkers. 2017;22:508\u201316.","journal-title":"Biomarkers"},{"key":"4112_CR62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/00003088-199120020-00004","volume":"20","author":"MR Holdiness","year":"1991","unstructured":"Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123\u201334.","journal-title":"Clin Pharmacokinet"},{"key":"4112_CR63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.0003-2409.2001.02399.x","volume":"57","author":"MA Rose","year":"2002","unstructured":"Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57:451\u201362.","journal-title":"Anaesthesia"},{"key":"4112_CR64","unstructured":"Katzung BG, Masters SB, Trevor AJ Basic & Clinical Pharmacology. 12th ed. USA: McGraw-Hill Medical; 2012."},{"key":"4112_CR65","doi-asserted-by":"publisher","first-page":"108827","DOI":"10.1016\/j.jneumeth.2020.108827","volume":"343","author":"G Oeltzschner","year":"2020","unstructured":"Oeltzschner G, Z\u00f6llner HJ, Hui SCN, Mikkelsen M, Saleh MG, Tapper S, et al. Osprey: open-source processing, reconstruction & estimation of magnetic resonance spectroscopy data. J Neurosci Methods. 2020;343:108827.","journal-title":"J Neurosci Methods"},{"key":"4112_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pscychresns.2018.07.003","volume":"279","author":"RJ Maddock","year":"2018","unstructured":"Maddock RJ, Caton MD, Ragland JD. Estimating glutamate and Glx from GABA-optimized MEGA-PRESS: off-resonance but not difference spectra values correspond to PRESS values. Psychiatry Res Neuroimaging. 2018;279:22\u201330.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"4112_CR67","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/mrm.22060","volume":"62","author":"C Gasparovic","year":"2009","unstructured":"Gasparovic C, Neeb H, Feis DL, Damaraju E, Chen H, Doty MJ, et al. Quantitative spectroscopic imaging with in situ measurements of tissue water T1, T2, and density. Magn Reson Med. 2009;62:583\u201390.","journal-title":"Magn Reson Med"},{"key":"4112_CR68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0271678X211045449","volume":"42","author":"Y Takado","year":"2022","unstructured":"Takado Y, Takuwa H, Sampei K, Urushihata T, Takahashi M, Shimojo M, et al. MRS-measured glutamate versus GABA reflects excitatory versus inhibitory neural activities in awake mice. J Cereb Blood Flow Metab. 2022;42:197\u2013212.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4112_CR69","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuropharm.2013.05.042","volume":"76","author":"X Li","year":"2014","unstructured":"Li X, Semenova S, D\u2019Souza MS, Stoker AK, Markou A. Involvement of glutamatergic and GABAergic systems in nicotine dependence: implications for novel pharmacotherapies for smoking cessation. Neuropharmacology. 2014;76:554\u201365.","journal-title":"Neuropharmacology"},{"key":"4112_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12986","volume":"26","author":"P Faulkner","year":"2021","unstructured":"Faulkner P, Lucini Paioni S, Kozhuharova P, Orlov N, Lythgoe DJ, Daniju Y, et al. Daily and intermittent smoking are associated with low prefrontal volume and low concentrations of prefrontal glutamate, creatine, myo-inositol, and N-acetylaspartate. Addiction Biol. 2021;26:e12986.","journal-title":"Addiction Biol"},{"key":"4112_CR71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1503\/jpn.160228","volume":"43","author":"B Romeo","year":"2018","unstructured":"Romeo B, Choucha W, Fossati P, Rotge JY. Meta-analysis of central and peripheral \u03b3-aminobutyric acid levels in patients with unipolar and bipolar depression. J Psychiatry Neurosci. 2018;43:58\u201366.","journal-title":"J Psychiatry Neurosci"},{"key":"4112_CR72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0920-1211(01)00214-5","volume":"45","author":"A Richens","year":"2001","unstructured":"Richens A. Proof of efficacy trials: cross-over versus parallel-group. Epilepsy Res. 2001;45:43\u20137.","journal-title":"Epilepsy Res"},{"key":"4112_CR73","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1001\/jamapsychiatry.2023.2726","volume":"80","author":"WH Mellick","year":"2023","unstructured":"Mellick WH, Tolliver BK, Brenner HM, Anton RF, Prisciandaro JJ. Alcohol cue processing in Co-occurring bipolar disorder and alcohol use disorder. JAMA Psychiatry. 2023;80:1150\u20139.","journal-title":"JAMA Psychiatry"},{"key":"4112_CR74","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/mrm.21696","volume":"60","author":"PG Mullins","year":"2008","unstructured":"Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med. 2008;60:964\u20139.","journal-title":"Magn Reson Med"},{"key":"4112_CR75","unstructured":"Shungu DC, Mao X, Gu M, Milak MS, Weiduschat N, Mayer D, et al., editors. Glx\u2019measured by J-editing\/MEGA-PRESS is primarily \u2018pure\u2019glutamate\u2026 or is it. Proc 21th Annual Meeting ISMRM, Salt Lake City. 2013."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04112-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04112-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04112-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:03:20Z","timestamp":1787339000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04112-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4112"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04112-4","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Prisciandaro and Mellick were funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr Anton reported grants from the NIAAA and a K05 Career Development Grant from the National Institutes of Health during the conduct of the study; personal fees from Alkermes, Denovo, Dicerna, Foxo Bioscience, Imbrium, Otsuka, and Saphosyne Pharma as consultant; and grants from Laboratorio Farmaceutico C.T. outside the submitted work. No other disclosures were reported.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"399"}}